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Genetic understanding of motor neuron disease (MND) has evolved greatly in the past 10 years, including
the recent identification of association between MND and variants in TBK1 and NEK1. Our aim was to
determine the frequency of pathogenic variants in known MND genes and to assess whether variants in
TBK1 and NEK1 contribute to the burden of MND in the Scottish population. SOD1, TARDBP, OPTN, TBK1,
and NEK1were sequenced in 441 cases and 400 controls. In addition to 44 cases known to carry a C9orf72
hexanucleotide repeat expansion, we identified 31 cases and 2 controls that carried a loss-of-function or
pathogenic variant. Loss-of-function variants were found in TBK1 in 3 cases and no controls and, sepa-
rately, in NEK1 in 3 cases and no controls. This study provides an accurate description of the genetic
epidemiology of MND in Scotland and provides support for the contribution of both TBK1 and NEK1 to
MND susceptibility in the Scottish population.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Motor neuron disease (MND) is a rapidly progressive and fatal
neurodegenerative disorder, characterized by loss of motor neuron
function. Presentations can include limb onset, bulbar onset, or
cognitive/behavioural disease, reflecting variable involvement of
the uppermotor neurons, lower motor neurons and frontotemporal
cortex (Turner and Swash, 2015). Age and site of onset, rate of dis-
ease progression and clinical syndrome vary considerably between
cases, presenting difficulties for diagnosis and diseasemanagement.
Phenotype data from Scottish MND cases are available through
the Scottish Motor Neuron Disease Register (SMNDR), a prospectiveand Experimental Medicine,
ity of Edinburgh, Edinburgh,
Centre for Motor Neurone
UK. Tel.: 0131 465 9519; fax:
), siddharthan.chandran@ed.
nc. This is an open access article unpopulation-based record of all cases diagnosed with MND, which
has been operational since 1989 (The Scottish Motor Neuron
Disease Research Group, 1992). In Scotland, there is a predicted
annual crude incidence of MND of 2.38 per 100,000 of the popu-
lation (Forbes et al., 2007). Mean survival from symptom onset to
death is 2.8 years (Forbes et al., 2007), albeit with a variable tra-
jectory depending on the clinical syndrome.
Substantial progress in understanding the genetic landscape of
MND has occurred over the last 10 years, including associationwith
dominant variants at several genetic loci (Renton et al., 2014).
Although the majority of cases of MND present without a family
history (w90%), variants in the same genes are thought to
contribute to the genetic etiology of both familial and apparently
sporadic cases. In recent series, pathogenic variants in known genes
have been found in around 70% of the cases with a family history
and 10% of the cases with no family history (Renton et al., 2014). The
main contributors in the UK and other European populations are
expansions of an intronic hexanucleotide repeat in C9orf72 and
missense variants in SOD1 and TARDBP (Abel, 2016; Abel et al., 2013;
Renton et al., 2014). Although the incidence of MND-associatedder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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screening of an unselected Scottish cohort for variants in SOD1
identified a high frequency of the I114T variant, which was found in
9% cases (Jones et al., 1995), and more recently C9orf72 expansions
were found in 11% of Scottish cases (Cleary et al., 2016). Two genes,
TBK1 and NEK1, have recently been associated with MND, with each
thought to account for a small proportion of cases, although they
have not been screened in the Scottish MND population (Brenner
et al., 2016; Cirulli et al., 2015; Freischmidt et al., 2015; Kenna
et al., 2016).
In families where affected individuals carry the same MND-
associated variant, for example SOD1 I114T, the phenotype can be
extremely variable (Lopate et al., 2010). This phenotypic heteroge-
neity, along with previous reports of pathogenic variants in more
than one MND gene in the same affected individual (oligogenic
cases; Bury et al., 2016; Cady et al., 2015; Chio et al., 2012b; Kenna
et al., 2013; Lattante et al., 2012; van Blitterswijk et al., 2012), has
led to a hypothesis that disease risk and subsequent phenotype is
determined by a combination of genetic factors and modifiers,
rather than a single genetic variant, in combination with environ-
mental triggers, as described in the multistep hypothesis of MND
(Al-Chalabi et al., 2014).
In this study, we report a multi-gene screen of MND cases and
controls from the Scottish population. Our aim was to determine
the contribution of variants in different genes to cases of MND in
Scotland, to investigate whether variants in TBK1 and NEK1
contribute to the burden of cases and to assess the association of
variants in MND genes with disease phenotype.
2. Materials and methods
2.1. MND case recruitment and control samples
MND cases were recruited through the SMNDR. The registration
process achieved high ascertainment coverage (98% in 1989e98;
Forbes et al., 2007), providing a cohort representative of the
national MND population. Details of methodology of recruitment
have been reported previously (The Scottish Motor Neuron Disease
Research Group, 1992); latterly the El Escorial classification system
was adopted (Brooks, 1994; Brooks et al., 2000). Recruited cases
included individuals aged 16 with probable or definite amyo-
trophic lateral sclerosis and individuals with MND subtypes (pro-
gressive bulbar palsy, progressive muscular atrophy and primary
lateral sclerosis). Individuals provided written consent for DNA
extraction and genetic studies.
Four hundred forty-one samples, obtained from cases diagnosed
with MND in Scotland in the years 1989e2014, were included in
this study, which included 3 pairs of related individuals (2 brothers,
2 first cousins, and 2 first cousins once removed). Case records were
examined for 7 phenotypic characteristics: sex, age at onset, age at
diagnosis, time to diagnosis, duration of disease (until death or final
data review [20th April 2016]), site of onset (bulbar or spinal), and
family history of MND. Individuals were classified as having a
family history of MND if a first, second, or third degree relative had
been known to have MND, as for cases. The study did not include
the presence of frontotemporal dementia (FTD) alone as a criterion
for positive family history. Five individuals were lost to follow-up
due to relocation from Scotland, and survival dates were censored
to date of last contact. The cohort was screened for expansions of
the C9orf72 intronic hexanucleotide repeat, as described by Cleary
et al. (2016). A subset of the cohort had been screened for vari-
ants in SOD1 in several previous studies (Hayward et al., 1998; Jones
et al., 1995; Swingler et al., 1995).
Five MND cases, each with a variant in 1 of the 5 genes
sequenced, were included as positive controls; these were takenfrom the cohort described by Cirulli et al. (2015). Four hundred
ethnicity and sex-matched healthy controls were selected from the
Generation Scotland Donor DNA databank (Kerr et al., 2010). The
selected controls were aged56 at the time of collection (20% aged
50e56, 66% aged 60e65, 14% aged 66þ); an older cohort was
chosen to minimize inclusion of young subjects who could go onto
develop MND later in life.
2.2. Targeted amplification and sequencing
Five genes were sequenced: SOD1, TARDBP, OPTN, TBK1, and
NEK1; these will be referred to hereafter as the MND gene panel.
The panel includes the recently associated TBK1 and NEK1, along-
side genes that are among the largest contributors to cases in UK
and European populations (SOD1, TARDBP, and OPTN), after C9orf72
(Abel, 2016; Abel et al., 2013; Renton et al., 2014).
Primers for 120 amplicons (Supplementary Table 1) were
designed according to the Fluidigm Access Array protocol (Fluid-
igm). The primers amplified the coding regions of these 5 genes
(Supplementary Table 2), excluding a total of 312bp of coding
sequence across the 5 genes, due to primer design constraints. The
Fluidigm Access Array was used for amplification, following the
manufacturer’s multiplex amplicon tagging protocol, with 2 mod-
ifications (Martyna Adamowicz-Brice, personal communication);
an additional 1:1 AMPure XP (Agencourt) cleanup step was intro-
duced post-harvesting and the subsequent dilution step was
removed. The amplicon library was sequenced on an Illumina
MiSeq with 2150-bp reads. Each batch of 48 samples included at
least one water blank as a negative control. The positive control
samples were each run in 2 independent batches.
2.3. Read mapping, sample filtering, variant calling, and annotation
Quality control of the amplicon sequencing data was performed
using FastQC (version 0.11.2) (Andrews, 2010). Primer sequences
were removed from the 50 ends of reads using the cutadapt tool
(version 1.7.1) with the ‘anchor’ option (Martin, 2011). The
maximum error rate for primer sequences was set to 10%. Reads
were mapped to the human genome reference sequence hs37d5
using BWA MEM (version 0.7.10; Li, 2013). Picard (version 1.85;
Broad Institute), and DepthOfCoverage GATK tool (version 3.3e0;
McKenna et al., 2010) were used to collect alignment and amplicon
coverage statistics. The median amplicon coverage of the negative
control sample was used to determine the threshold for including
samples from the same batch in further analysis. Only samples with
a median coverage that was >10 that of the negative control were
included. This removed 7 cases and 11 controls, leaving 434 cases
(432 independent) and 389 controls for further analysis. The Uni-
fiedGenotyper tool, as implemented in GATK version 2.6 (McKenna
et al., 2010), was used for variant calling. ANNOVAR (version 2014
Nov 12) was used to provide functional annotation of the variants
(Wang et al., 2010). Variants were annotated with reference to the
transcripts listed in Supplementary Table 2.
2.4. Variant filtering and validation
Intronic and synonymous variants, variants with a population
frequency greater than 1% in either the 1000 Genomes (October
2014 release; 1000 Genomes Project Consortium et al., 2015) or
ExAC v0.2 (Lek et al., 2016) data sets and variants with a frequency
>5% in our cohort were excluded from further analysis. Per-sample
variant calls were filtered to exclude calls with a read depth <50 or
an allele balance <0.3. Filtered variants were validated by Sanger
sequencing. One sample failed to amplify using PCR at variant
validation stage and was excluded from further analysis, leaving
Table 1
Phenotypic characteristics of MND cases (n ¼ 433)
Phenotypic characteristic Summary statistic Values
Sex Female (%) 177/433 (41)
Age of onset (y) Mean (SD)
Range
59.5 (12.9)
14e94
Age of diagnosis (y) Mean (SD)
Range
61.1 (12.6)
19e94
Time to diagnosis (mo) Median (IQR)
Range
12 (6, 22)
0e386
Duration of disease from onset (mo) Median (IQR)
Range
42 (25, 73.5)
4e583
Duration of disease from diagnosis (mo) Median (IQR)
Range
25 (12, 55.5)
0e309
Site of onset Bulbar (%) 126/432 (29)
Family history of MND Yes (%) 44/429 (10)
Duration of disease: survival until (i) death (n ¼ 367), (ii) data censorship at 20th
April 2016 (n ¼ 61), or (iii) date of last contact (n ¼ 5). Includes 2 pairs of related
individuals.
Key: SD, standard deviation.
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SOD1 exon 1, and this exon was excluded from the analysis.
Following exclusion of this exon, 5 false positives remained, which
were excluded from downstream analysis. Validated variants were
submitted to Clinvar. The known variants in the positive controls
were identified in both assays in which they were tested.
2.5. Assessing variant pathogenicity
Stop-gain, frameshift, and splice site variants were categorized
according to their predicted effect on protein function. Missense
variants reported as disease-causing in associationwithMND in the
Human Gene Mutation Database (Stenson et al., 2008) were cate-
gorized as pathogenic. The remaining missense variants were
categorized according to in silico scores of pathogenicity and con-
servation. The scores used are listed below, with the thresholds for
supporting pathogenicity/conservation in brackets: SIFT (¼D),
PolyPhen HDIV (¼P/D), LRT (¼D), Mutation Taster (¼D), Mutation
Assessor (¼M/H), FATHMM (¼D), CADD phred (>15), GERP (>2),
phyloP (>2), and SiPhy (>10). Variants for which 7e10 in silico
measures supported pathogenicity/conservation were categorized
as likely pathogenic, variants with 4e6 measures supporting
pathogenicity/conservation were categorized as uncertain signifi-
cance, and variants with 0e3 measures supporting pathogenicity/
conservation were categorized as likely benign (Supplementary
Table 3).
2.6. ExAC reference exomes
The ExAC v0.3.1 reference exome data (Exome Aggregation
Consortium (ExAC); Lek et al., 2016) were used to provide an
additional, larger control population. It contains exome-wide vari-
ants identified in 60,706 individuals. For both TBK1 and NEK1, the
total number of loss-of-function or loss-of-function þ missense
alleles in ExAC were recorded (including filtered [non-pass] vari-
ants), excluding variants found in >1% individuals. The number of
ExAC individuals was reduced to reflect the average percentage of
individuals covered at 30 across each gene. For TBK1, an average of
w69% of individuals was covered at 30, giving 41,848 individuals
assumed to have sufficient depth for variant calling. ForNEK1, it was
w50%, giving 30,298 individuals.
2.7. Statistical analysis
Fisher’s exact tests were used in comparisons between the
number of variants in cases and controls (Sections 3.2, 3.4 and 3.5).
One-tailed tests were used because of the prior assumption that
cases contain more pathogenic variants than controls. Genotype-
phenotype association testing was used to compare clinical
phenotypes with different MND genotypes (Section 3.7). Only un-
related individuals (n¼ 431) were included in the analysis, with the
first individual recruited to the SMNDR from each pair retained for
analysis. Variables were examined for collinearity using Pearson’s
correlation coefficient. Age of onset and age at diagnosis were
highly correlated (Pearson’s correlation r ¼ 0.98, p < 5  107), as
were duration of disease from onset and duration of disease from
diagnosis (r ¼ 0.87, p < 5  107). Disease onset is more important
to disease biology than date of diagnosis, which relies on clinical
services; therefore, variables related to diagnosis were excluded
from genotype-phenotype association testing. Time to diagnosis
was also excluded from genotype-phenotype analysis, as this is a
derived variable. Univariate analysis was carried out for the
following variables: sex, age of onset, duration of disease from
onset, site of onset, and family history. Two-tailed Fisher’s exact test
was used for categorical data and t-test or Mann Whitney U testwas used for parametric and non-parametric continuous data,
respectively (Section 3.7). Variables with significant univariate as-
sociation at p  0.1 were inputted into binomial logistic regression
models dependent on gene. Logistic regression analysis was used to
test the hypothesis that significant variables were independently
associated with having a pathogenic or loss-of-function variant in
one of the genes tested. For the purposes of the model, age of onset
was grouped by decade. Results from logistic regression modeling
were considered significant if p < 0.05 (Section 3.7). SPSS Statistics
version 21 was used for all statistical analysis.
3. Results
3.1. MND case phenotypes
After sample filtering, 433 MND cases (431 independent)
remained, of which complete phenotypic data were obtained for
428 (99%; Table 1). Site of onset was unrecorded for 1 case. Family
history was unrecorded for 3 cases and was unknown for 1 case,
who was adopted. The cohort had a male to female ratio of 1.4:1
(Table 1). The mean age of onset was 59.5 years. Of the 443 cases in
this cohort, 367 (85%) had died before censorship date; median
duration of disease from onset for all the cases was 42 months. Of
the 430 independent cases for which site of onset was recorded,
304 (71%) had spinal onset MND. Of the 429 cases with recorded
family history, 44 (10%) had a family history of MND.
3.2. Identification of variants in MND genes
Targeted sequencing with the MND gene panel achieved a mean
coverage of 6280 per amplicon per sample. Following variant
filtering and validation (Section 2.4), at least one rare stop-gain,
splice site, frameshift, or missense variant was identified in 57/
433 cases and 19/389 controls (Supplementary Tables 4 and 5).
Following sample filtering (Section 2.3), the case population con-
tained 2 pairs of related individuals. The first pair (brothers) both
carried the SOD1 G94R variant, whereas the second pair (first
cousins) did not carry any variants in the MND gene panel that
passed variant filtering. Therefore, the results for the related in-
dividuals were concordant.
Thirty-seven unique variants were identified in either cases or
controls across the MND gene panel; of these, 3 were stop-gain, 3
were splice site, 3 were frameshift, and 28 were missense variants
(Supplementary Table 4). All stop-gain, splice site, and frameshift
variantswere categorized as loss-of-function, except for 3 variants. A
stop-gain variant in TARDBP was categorized as uncertain
Table 2
Variants identified across the MND gene panel, with their pathogenicity classification and frequency in cases and controls
Gene Loss-of-function Pathogenic Likely pathogenic Uncertain
significance
Likely benign Totalb
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
SOD1 0 0 22a 1 1 0 0 0 0 0 23a 1
TARDBP 0 0 4 0 0 0 1 0 0 0 5 0
OPTN 0 0 1 1 2 1 1 0 0 0 4 2
TBK1 3 0 0 0 2 0 1 1 0 0 6 1
NEK1 3 0 0 0 10 8 6 4 2 4 21 16
a Includes 1 pair of brothers.
b The total includes 1 case with a pathogenic variant in OPTN and a loss-of-function variant in TBK1; a case with a pathogenic variant in TARDBP and a variant of uncertain
significance in NEK1; and a control with a pathogenic and likely pathogenic variant in OPTN.
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expected to result in nonsense-mediated decay. There were also 2
splice site variants inNEK1 predicted to result in the in-frame loss of
a single exon (Brunak et al., 1991), which were categorized as un-
certain significance. Therefore, of the 37 unique variants identified, 6
were categorized as loss-of-function, 7 pathogenic, 11 likely patho-
genic, 8 uncertain significance, and 5 likely benign (Supplementary
Table 4).
In total, 31 MND cases and 2 controls carried at least one loss-of-
function or pathogenic variant across the MND gene panel (Table 2
and Supplementary Table 5; Fisher’s p ¼ 1.761  107). Taken
together with prior findings that 44 of the 431 independent cases
contain a pathogenic intronic hexanucleotide repeat expansion in
C9orf72 (100 repeats; Cleary et al., 2016), 74 independent cases
(17%) carried at least one pathogenic or loss-of-function variant
(Table 2 and Supplementary Table 5). This represented 26/42 (62%)
of cases with a family history and 47/385 (12%) of cases with no
family history (Fig. 1).
3.3. Variants in SOD1, OPTN, and TARDBP
After C9orf72, the largest genetic contributor to cases in our
study was SOD1, with pathogenic or likely pathogenic variantsNo variant, 
38%
C9orf72, 33%
SOD1, 29%
TBK1, 2%
No variant C9orf72 SOD1 TBK1
A familial MND (n=42) B
Fig. 1. Proportion of cases with a pathogenic or loss-of-function variant in genes on the MN
known family history. Each pie chart includes one digenic case that is counted for both ofobserved in 22/431 independent MND cases (5%) and 1/389 con-
trols (0.3%; Table 2 and Supplementary Tables 4 and 5). The I114T
Scottish founder mutation was observed in 18 cases (4%) and 1
control (0.3%). Of all cases, 29% of familial and 2% of sporadic carry a
pathogenic variant in SOD1.
Pathogenic variants in TARDBP were observed in 4/431 (1%)
cases and no controls. This is in addition to a stop-gain variant of
uncertain significance, observed in one case. For OPTN, at least one
pathogenic or likely pathogenic variant was observed in 3/431 (1%)
cases and 1/389 controls (0.3%). The single pathogenic variant in
OPTN, Q314L, was observed in 1 case and 1 control. There is no
functional evidence to support the association of this variant with
MND and, although in previous studies in silico evidence has sug-
gested a pathogenic role for the variant in MND (Del Bo et al., 2011),
the occurrence of the variant in 1 case and 1 control in our data
suggests that the variant either has variable penetrance or is not
pathogenic for MND. OPTN therefore appears to contribute to very
few cases of MND in the Scottish population.
3.4. Assessing the association of variants in TBK1 with MND
Several previous studies have reported dominant variants in
TBK1 in cases of MND, FTD, and MND-FTD, accounting forsporadic MND (n=385)
No variant, 
88%
C9orf72, 8%
SOD1, 2%
TARDBP, 1% NEK1, 0.80% TBK1, 0.50% OPTN, 0.30%
No variant C9orf72 SOD1 TARDBP NEK1 TBK1 OPTN
D gene panel or in C9orf72. (A): cases with a family history; (B): sporadic cases with no
the genes in which a pathogenic or loss-of-function variant is found.
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H.A. Black et al. / Neurobiology of Aging xxx (2016) 1.e1e1.e10 1.e5approximately 1% of all cases (Borghero et al., 2016; Cirulli et al.,
2015; Exome Aggregation Consortium (ExAC); Freischmidt et al.,
2015; Gijselinck et al., 2015; Le Ber et al., 2015; Pottier et al.,
2015; Shu et al., 2016; Tsai et al., 2016; van Rheenen et al., 2016;
Williams et al., 2015). In our study, we observed 6 cases and 1
control with a rare stop-gain, splice site frameshift, or missense
variant in TBK1 (Section 2.4; Table 2 and Supplementary Table 5;
Fisher’s p ¼ 0.080). When compared with the ExAC reference data
set (Exome Aggregation Consortium (ExAC); Lek et al., 2016), this
result is not significant (Fisher’s p ¼ 0.238). When looking only at
loss-of-function variants, 3 cases and no controls contained a loss-
of-function variant in TBK1 (Fisher’s p ¼ 0.145). When compared
with the ExAC reference data set, where the frequency of loss-of-
function variants was 0.03%, this represents a statistically signifi-
cant excess (Fisher’s p ¼ 4.370  104; Exome Aggregation
Consortium (ExAC); Lek et al., 2016).
3.5. Assessing the association of variants in NEK1 with MND
Loss-of-function variants in NEK1 have been associated with
MND in two recent studies of both familial and sporadic MND cases
(Brenner et al., 2016; Kenna et al., 2016), following an earlier study
of mostly sporadic cases that highlighted NEK1 as a candidate gene
(Cirulli et al., 2015; Exome Aggregation Consortium (ExAC)). These
3 studies estimate that loss-of-function variants in NEK1 contribute
to approximately 1% of cases. In this study, we observe 3 cases and
no controls with a variant predicted to result in loss-of-function of
NEK1 (Table 2 and Supplementary Table 5; Fisher’s p ¼ 0.145).
When compared with the ExAC reference data set, where the fre-
quency of loss-of-function variants was 0.3%, our result remains
nonsignificant (Fisher’s p ¼ 0.143; Exome Aggregation Consortium
(ExAC); Lek et al., 2016). Regarding missense variants in NEK1
(Section 2.4; Table 2 and Supplementary Table 5), we observe 16
cases and 16 controls with an NEK1 missense variant, which is not
statistically significant (Fisher’s p ¼ 0.453).
3.6. Cases carrying 2 variants in MND-associated genes
There are several reports of MND cases that carry MND-
associated variants in more than 1 gene (Bury et al., 2016; Cady
et al., 2015; Chio et al., 2012b; Kenna et al., 2013; Lattante et al.,
2012; van Blitterswijk et al., 2012). We observed 5 cases and 1
control carrying 2 different rare stop-gain, frameshift, splice site, or
missense variants (Section 2.4) either across theMND gene panel or
in C9orf72 (Table 3). Two cases, MND-0040 and MND-0434, and no
controls carry 2 variants that are predicted to be either pathogenic
or loss-of-function; these will be referred to as digenic cases
(Table 3). Both digenic cases have an age of onset within 2 standard
deviations of the mean and a typical disease duration (Table 3).
However, as discussed in Section 3.3, the pathogenicity of the
variant Q314L in OPTN in MND-0040 is unclear.
Of the remaining cases with two rare variants in MND-
associated genes, case MND-0119 carries 1 pathogenic variant and
1 variant of uncertain significance and has a typical age of onset and
disease duration. Case MND-0158, who carries 1 pathogenic and 1
likely pathogenic variant, had a young age of onset (26 years, >2.5
standard deviations from the mean) and long disease duration
(142 months, above 90th percentile). MND-0211 also carries 1
pathogenic and 1 likely pathogenic variant and had a typical age of
onset, but disease duration at the lower end of the spectrum
(16 months, equal to the 10th percentile). Interestingly, 3 of the 5
cases (60%) carrying 2 rare stop-gain, splice site, frameshift, or
missense variants in MND genes (including C9orf72 expansions)
had a bulbar site of onset, which is higher than the 29% observed
across all MND cases in the cohort.
Ta
b
le
4
G
en
ot
yp
e-
p
h
en
ot
yp
e
te
st
s
of
as
so
ci
at
io
n
co
m
p
ar
in
g
p
h
en
ot
yp
e
w
it
h
p
at
h
og
en
ic
or
lo
ss
-o
f-
fu
n
ct
io
n
va
ri
an
ts
in
d
if
fe
re
n
t
M
N
D
ge
n
es
Ph
en
ot
yp
ic
ch
ar
ac
te
ri
st
ic
St
at
is
ti
c
N
o
Pa
th
(n
¼
35
7)
Pa
th
/L
oF
(n
¼
74
)
C
9o
rf
72
(n
¼
44
)
SO
D
1
in
c.
I1
14
T
(n
¼
21
)
SO
D
1
I1
14
T
(n
¼
18
)
TA
R
D
B
P
(n
¼
4)
TB
K
1
(n
¼
3)
N
EK
1
(n
¼
3)
D
ig
en
ic
(n
¼
2)
Se
x
Fe
m
al
e
(%
)
Fi
sh
er
’s
13
8
(3
9)
-
39
(5
3)
p
[
0.
02
8
21
(4
8)
p
¼
0.
41
9
12
(5
7)
p
¼
0.
17
1
11
(6
1)
p
[
0.
09
0
3
(7
5)
p
¼
0.
31
0
2
(6
7)
p
¼
0.
57
1
1
(3
3)
p
¼
1.
00
0
1
(5
0)
p
¼
1.
00
0
A
ge
of
on
se
t
(y
)
M
ea
n
(S
D
)
M
ea
n
d
if
f
C
I
t-
te
st
60
.2
(1
2.
9)
-
56
.3
(1
2.
1)
0
.3
9
0
.7
2
to
0.
07
p
[
0.
01
8
55
.6
(1
1.
4)
0
.4
4
0
.8
4
to
0.
04
p
¼
0.
26
6
55
.9
(1
4.
4)
0
.3
8
0
.9
4
to
0.
18
p
¼
0.
18
6
59
.4
(1
2.
0)
0
.0
1
0
.6
2
to
0.
59
p
¼
0.
96
7
61
.3
(7
.8
)
0.
18 1
.0
9
to
1.
44
p
¼
0.
78
6
48
.7
(6
.4
)
1
.0
9
2
.5
5
to
0.
36
p
¼
0.
14
1
66
.7
(1
0.
6)
0.
72 0
.7
4
to
2.
18
p
¼
0.
33
2
45
.0
(1
.4
)
1
.4
6
3
.2
4
to
0.
32
p
¼
0.
10
8
D
u
ra
ti
on
of
d
is
ea
se
fr
om
on
se
t
(m
o)
M
ed
ia
n
(I
Q
R
)
M
an
n
-W
h
it
n
ey
42
.0
(4
8)
-
37
.0
(4
5)
U
¼
11
,7
84
.0
p
¼
0.
14
4
38
.5
(5
3)
U
¼
76
44
.0
p
¼
0.
26
6
37
.0
(6
7)
U
¼
38
47
.5
p
¼
0.
41
1
38
.0
(8
9)
U
¼
34
83
.0
p
¼
0.
65
2
39
.5
(1
7)
U
¼
83
4.
0
p
¼
0.
93
6
34
.0
(-
)
U
¼
55
8.
5
p
¼
0.
69
8
31
.0
(-
)
U
¼
61
0.
5
p
¼
0.
88
4
28
.5
(-
)
U
¼
27
1.
5
p
¼
0.
37
0
Si
te
of
on
se
t
B
u
lb
ar
%
Fi
sh
er
’s
10
3
(2
9)
-
23
(3
1)
p
¼
0.
77
9
18
(4
1)
p
[
0.
08
2
1
(5
)
p
[
0.
01
2
1
(6
)
p
[
0.
03
1
2
(5
0)
p
¼
0.
58
4
2
(6
7)
p
¼
0.
20
7
0
(0
)
p
¼
0.
55
9
1
(5
0)
p
¼
0.
50
1
Fa
m
ily
h
is
to
ry
of
M
N
D
Y
es
(%
)
Fi
sh
er
’s
16
(5
)
-
26
(3
6)
p
<
5
3
10
7
14
(3
3)
p
[
1
3
10

5
12
(5
7)
p
<
5
3
10

7
9
(5
0)
p
[
9
3
10

6
0
(0
)
p
¼
1.
00
0
1
(3
3)
p
¼
0.
26
8
0
(0
)
p
¼
1.
00
0
1
(5
0)
p
¼
0.
18
7
Si
gn
ifi
ca
n
t
as
so
ci
at
io
n
s
(p
<
0.
10
)
ar
e
h
ig
h
lig
h
te
d
in
bo
ld
.C
I,
95
%
co
n
fi
d
en
ce
In
te
rv
al
;
Lo
F,
lo
ss
-o
f-
fu
n
ct
io
n
;
M
ea
n
d
if
f,
d
if
fe
re
n
ce
in
m
ea
n
s
be
tw
ee
n
gr
ou
p
of
in
te
re
st
an
d
al
lo
th
er
ca
se
s;
Pa
th
,p
at
h
og
en
ic
va
ri
an
t,
or
ex
p
an
si
on
.
Fu
ll
p
h
en
ot
yp
e
d
at
a
ar
e
gi
ve
n
in
Su
p
p
le
m
en
ta
ry
Ta
bl
e
6.
H.A. Black et al. / Neurobiology of Aging xxx (2016) 1.e1e1.e101.e6CONTROL-0325, who was aged 56e60 at the time of collection,
carries 2 missense variants in OPTN; one considered pathogenic;
and 1 likely pathogenic. The pathogenicity of variant Q314L, as
discussed in Section 3.3, is unclear. The data available do not allow
confirmation of whether the 2 OPTN variants are found in cis or in
trans and, therefore, if both allelic copies of OPTN carry a variant. It is
also unclear whether both variants are expected to contribute to
MND pathogenesis; if so, they would be expected to be associated
with variable penetrance. As no follow-up information is available
for controls, there is a small chance the control developed MND
after sample donation, although this is unlikely given the lifetime
risk of MND.
3.7. Genotype-phenotype associations
Genotype-phenotype association testing was used to determine
the relationship between carrying a variant in a specific gene and 5
phenotypic markers (Table 4 and Supplementary Table 6). MND
cases carrying the SOD1 I114T founder variant were also analyzed
independently of other SOD1 variants in view of the high incidence
of this specific variant in the Scottish population. Only unrelated
cases were included in the analysis (n ¼ 431).
Univariate analyses comparing cases with a pathogenic or loss-
of-function variant (including C9orf72 expansions) to cases without
such a variant found associations between carrying a pathogenic or
loss-of-function variant and a family history of MND (Fisher’s p
< 5107), a younger age of onset (t-test p¼ 0.018), and female sex
(Fisher’s p ¼ 0.028; Table 4). A logistic regression model evaluating
the possible independent associations of these variables with
variant status explained 21% of the variance between cases with
and without a pathogenic or loss-of-function variant (Nagelkerke
R2). Independent associations were found for positive family his-
tory (p < 5  107, OR 10.88, 95% CI 5.38e22.01), decreasing age of
onset by decade (p ¼ 0.018, OR 0.77, 95% CI 0.62e0.96), and female
sex (p ¼ 0.028, OR 1.88, 95% CI 1.07e3.30; Table 5).
A high proportion of cases carrying a pathogenic SOD1 variant
had spinal onset disease (95%) compared with the frequency of
spinal onset in all other case (Fisher’s p ¼ 0.012). Carrying a path-
ogenic SOD1 variant was also associated with having a family his-
tory of MND, compared to all other cases (Fisher’s p < 5  107;
Table 4). When examining SOD1 I114T carriers in isolation, these 2
factors remained significant (site of onset Fisher’s p ¼ 0.031, family
history Fisher’s p ¼ 9  106; Table 4). Twenty-seven percent of the
variance between SOD1 pathogenic variant carriers and all other
cases was explained by the model (Nagelkerke R2). Spinal onset
disease (p ¼ 0.044, OR 8.25, 95% CI 1.06e64.49) and family history
of MND (p < 5  107, OR 16.21, 95% CI 6.21e42.33) were inde-
pendently associated with carrying a SOD1 pathogenic variant. Af-
ter initial modeling for the SOD1 I114T variant (using sex, site of
onset, and family history), sex and site of onset did not achieve
significance at the p ¼ 0.1 threshold and were removed. On revised
modeling, family history remained significant (p ¼ 1  106, OR
11.39, 95% CI 4.23e30.67; Table 5), explaining 16% of the variance
(Nagelkerke R2).
Univariate analysis showed carrying a C9orf72 expansion was
associated with having a family history of MND (Fisher’s
p ¼ 1  105; Table 4). Site of onset did not reach statistical sig-
nificance (p < 0.05), but met the criteria required for inclusion in
the logistic regression model (Fisher’s p ¼ 0.082; Table 4). The lo-
gistic regression model explained 12% of the variance between
carriers of C9orf72 expansions and those without (Nagelkerke R2).
Bulbar onset disease (p ¼ 0.021, OR 2.23, 95% CI 1.13e4.42) and
family history (p ¼ 1  106, OR 6.86, 95% CI 3.19e14.77) were
significantly and independently associated with carrying a C9orf72
expansion (Table 5).
Table 5
Logistic regression modeling of genotype-phenotype tests of association for (i) cases
with a pathogenic or loss-of-function variant across the MND gene panel or C9orf72
expansion (ii) cases with a C9orf72 expansion (iii) cases with a SOD1 pathogenic
variant (iv) cases with the SOD1 I114T variant
Variant type Predictor p-value OR (CI)
Path/LoF
(n ¼ 74)
Female sex 0.028 1.88 (1.07e3.30)
Age of onset
(decade)
0.018 0.77 (0.62e0.96)
Family history
of MND
<5  107 10.88 (5.38e22.01)
C9orf72
(n ¼ 44)
Bulbar onset 0.021 2.23 (1.13e4.42)
Family history
of MND
1  106 6.86 (3.19e14.77)
SOD1
(n ¼ 21)
Spinal onset 0.044 8.25 (1.06e64.49)
Family history
of MND
<5  107 16.21 (6.21e42.33)
SOD1 I114T
(n ¼ 18)
Family history
of MND
1  106 11.39 (4.23e30.67)
Key: CI, 95% confidence interval; LoF, loss-of-function; OR, odds ratio; path, path-
ogenic variant or C9orf72 expansion.
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variant in one of the MND genes on survival was visualized using
a Kaplan-Meier plot (Fig. 2). Cases were grouped by genotype.
Survival was plotted for all cases, including the 15% of cases for
whom duration of disease was calculated from onset to date of last
contact/study truncation. No significant difference was found be-
tween groups (log rank p ¼ 0.276).4. Discussion
4.1. Genetic epidemiology of MND in Scotland
This study provides a detailed description of the genetic pa-
thology of MND in Scotland. We have identified 31 independent
cases carrying a pathogenic or loss-of-function variant across our
MND gene panel. The identification of pathogenic variants in 2
controls (0.5%) is comparable to previous studies and is explainedSurvival from Onset (Months)
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Fig. 2. Kaplan-Meier survival plot of MND cases grouped by genotype. C9orf72, path-
ogenic expansion identified; digenic, two pathogenic or loss-of-function variants
identified; Nil, no pathogenic or loss-of-function variant identified; other, pathogenic
or loss-of-function variant identified in TARDBP, TBK1, NEK1, or OPTN; SOD1, pathogenic
SOD1 variant identified.by the variable penetrance observed with variants in genes asso-
ciated with MND (Lopate et al., 2010; van Blitterswijk et al., 2012).
The Scottish MND population were comparable with other Eu-
ropean MND populations on demographic and disease character-
istics (Li et al., 1990; Logroscino et al., 2008; Traynor et al., 2000). A
positive family history in 10% of Scottish MND cases was compa-
rable recent population estimates (16% in the Irish population and
9% in a US population of European ancestry; Byrne et al., 2013;
Gibson et al., 2014). Our data show that, after C9orf72, variants in
SOD1 contribute to the largest proportion of MND cases (5%) in the
Scottish population, which is in the upper range compared with
other populations of European ancestry (Andersen, 2006; Renton
et al., 2014). This reflects the high frequency of the I114T variant,
which had previously been identified as a founder mutation with
variable penetrance in the Scottish population (Hayward et al.,
1996; Jones et al., 1993, 1995; Lopate et al., 2010). Although this
variant is less frequent than was observed previously in a smaller
cohort (Hayward et al., 1996), it is still found in 4% of cases when
assessed across our larger cohort and is found in 24% of those cases
in which a pathogenic variant was identified. In comparison,
pathogenic variants in TARDBP contribute to <1% of cases, compa-
rable to previous estimates in populations of European ancestry
(Renton et al., 2014), and pathogenic variants in OPTN are extremely
rare, which is similar to a previous study of the UK population
(Johnson et al., 2012).
Our data support a growing literature associating loss-of-
function variants in TBK1 with MND. Several previous studies
have associated dominant coding variants in TBK1 with MND. The
first study reported a significant excess of coding variants in TBK1,
excluding those predicted to be benign, in mostly sporadic cases
compared to controls (Cirulli et al., 2015). However, the biggest
excess was observed for loss-of-function variants. This was sup-
ported by a second study, which found a significant excess of loss-
of-function variants in TBK1, but only in familial cases (Freischmidt
et al., 2015). Several other studies, looking at MND, frontotemporal
dementia (FTD) and MND-FTD cases from both European and Asian
populations, have also reported variants in TBK1, mostly loss-
of-function (Borghero et al., 2016; Gijselinck et al., 2015; Le Ber
et al., 2015; Pottier et al., 2015; Shu et al., 2016; Tsai et al., 2016;
van Rheenen et al., 2016; Williams et al., 2015). In our study,
although the number of loss-of-function variants identified in TBK1
was not statistically significant when compared with our 389
controls, a significant difference was observed when compared
with the larger ExAC reference data set and the percentage of cases
carrying a loss-of-function variant in TBK1 was comparable to
previous studies (0.7% vs. <1% in previous studies [Cirulli et al.,
2015; Freischmidt et al., 2015]). Therefore, our data support the
association of loss-of-function variants in TBK1 with MND.
Similarly, the frequency of NEK1 loss-of-function variants in our
cases (0.7%) is comparable to previous studies (1%; Brenner et al.,
2016; Cirulli et al., 2015; Kenna et al., 2016); however, the obser-
vation of 3 loss-of-function variants in NEK1 in our cases was not
significantly different to that of our 389 controls or the ExAC
reference data set. Although the result does not provide formal
statistical significance for the association of loss-of-function vari-
ants in NEK1 with MND, as the frequency is comparable to other
studies, our result is supportive of these previous findings. We
observed the same number of missense variants in NEK1 in both
cases and controls, with little difference in the assigned pathoge-
nicity classifications. This is comparable to a recent study which
showed that, although one specific missense variant, R261H (clas-
sified as likely pathogenic in our study), was associated with MND,
collectively, missense variants showed very little difference in fre-
quency between sporadic cases and controls (Kenna et al., 2016). In
addition, the other variants in NEK1 causally related to the
H.A. Black et al. / Neurobiology of Aging xxx (2016) 1.e1e1.e101.e8development of MND in previous studies are loss-of-function var-
iants. There may therefore be some specific missense variants that
result in impaired NEK1 function, but collectively, this appears not
to be the case.
We identified 2 cases each carrying 2 variants classified as
pathogenic or loss-of-function in different MND genes (digenic
cases). As controls were not screened for hexanucleotide repeat
expansions in C9orf72, we were biased against identifying digenic
controls, so it is not clear whether our 2 digenic cases represent a
statistically significant excess. As each digenic case has a different
variant combination, it is not possible to obtain a detailed assess-
ment of how digenicity influences MND phenotype. Further
investigation of a larger number of digenic cases is required to
determine whether each variant contributes to disease pathogen-
esis, whether variants have an additive effect and to determine how
different variant combinations influence disease presentation.
4.2. Genotype-phenotype associations
Our genotype-phenotype analysis confirms the expected asso-
ciation thatMND cases with a family history of MND aremore likely
to carry a pathogenic or loss-of-function variant than cases with no
family history. The results also indicate that a young age of onset of
MND is a significant independent predictor of carrying a pathogenic
variant. Although this finding requires replication, it suggests that,
in addition to the presence of a family history, clinicians should use
a lower threshold for genetic testing in cases developing symptoms
of MND before the mean age of onset. The analysis also suggests
that female sex is significantly associated with carrying a patho-
genic or loss-of-function variant. This most likely reflects the equal
number of males and females carrying variants pathogenic for
MND, within an MND case population which overall has a male
bias. This result is also consistent with the liability threshold ge-
netic model, which would suggest that, as females have an overall
lower risk than males of developing MND, they must accumulate a
larger burden of risk factors to pass the threshold for disease onset
(Falconer, 1965). The logistic regression model concerned only ex-
plains 21% of the difference between cases with a pathogenic or
loss-of-function variant and those without, suggesting that addi-
tional phenotypic markers are acting as confounders.
Our study confirms that C9orf72 expansion carriers are more
likely to present with bulbar disease than other MND cases (Byrne
et al., 2012; Chio et al., 2012a; Millecamps et al., 2012). However,
our model explained only 12% of the variance, and substantial
phenotypic heterogeneity among C9orf72 carriers, particularly in
terms of cognitive symptoms, is widely recognized (Rohrer et al.,
2015). Cognitive profile may be an important parameter to
explore further in characterizing this cohort of cases. SOD1 variant
carriers in our cohort were relatively homogeneous in terms of site
of onset, with a bias toward spinal onset MND. This mirrors clinical
accounts of lower limb onset disease as a common presentation of
SOD1 MND (Millecamps et al., 2010). A high proportion of I114T
carriers also had spinal onset disease, despite failing to achieve
statistical significance on logistic regression modeling. However,
heterogeneity in I114T carriers for age of onset (range 42e84 years)
and duration of disease from onset (11e172 months) was notable
and suggests any biological link to these features is absent or
extremely weak.
4.3. Limitations
There is increasing need for standardization of methods to
assign variant pathogenicity. The recent American College of
Medical Genetics guidelines (Richards et al., 2015) sought to
address this; however, they are designed principally for monogenic,Mendelian disorders andmay not be suitable for complex disorders
such as MND, with a preponderance of sporadic cases and consid-
erable variability in the penetrance of pathogenic variants. The lack
of segregation data and large number of singleton variants meant
that using in silico predictors of variant pathogenicity and conser-
vationwere most appropriate for assessing variant pathogenicity in
our study, although it is clear that standardization of the methods
used to assign pathogenicity for potential MND-associated variants
is required.
One limitation of the combined use of the Fluidigm Access Array
and Illumina MiSeq is the number of false positives we observed.
The large number in SOD1 exon 1 is most likely due to the high GC
content of this exon (Timothy J Aitman, unpublished data). Exclu-
sion of this exon could have reduced the overall variant detection
rate for SOD1, as many pathogenic missense variants have been
reported in this exon (Stenson et al., 2008). After excluding this
exon, 6% of the remaining variants also failed to validate. This could
be due to the high number of cycles in the 2 rounds of PCR (35 and
15 cycles respectively) required to generate the sequencing library.
Therefore, it is essential to use Sanger sequencing to validate vari-
ants identified through this protocol, as is typically applied
following high-throughput sequencing.
Survival analysis between MND cases carrying pathogenic or
loss-of-function variants in different genes did not achieve statis-
tical significance. Possible limitations to this analysis include sam-
ple size and lack of data relating to interventions that influence
survival (e.g., noninvasive ventilation, gastrostomy insertion, and
use of riluzole).
5. Conclusions
In summary, we identified a pathogenic or loss-of-function
variant in an MND gene in 17% of our cohort of MND cases from
the Scottish population. Our data give supporting evidence for the
association of loss-of-function variants in TBK1 and NEK1 with
MND. Genotype-phenotype association testing has highlighted that
MND cases with a family history or with a young age of onset are
significantly more likely to carry a genetic variant pathogenic for
MND and suggests that cases presenting with a young age of onset
should be referred for genetic testing, in addition to cases with a
family history.
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